INTRODUCTIONRESULTS
summarizes data obtained from both groups of patients. Only 13 genes showed similar changes in the two groups of patients, and the overall changes indicated that patients with MD differed from those with SD.
Patients with MD
Totally, 174 genes showed changes in expression, which was a relatively low number. Genes in the neuron category using gene functional classification (The term "category using gene functional classification" will hereinafter be abbreviated "category") tended to be downregulated, while most genes showing changes in the muscle category were upregulated. Genes related to muscle components and genes involved in muscle movement were also upregulated. The expression of only two genes related to energy production was altered, but both were important genes in the glycolysis pathway and both were upregulated. Except for these functional categories, we did not find any large functional clusters. Some genes involved in cell division and cell proliferation were downregulated. However, genes linked to apoptosis and stress markers were not upregulated (Table 1) .
Patients with SD
Totally, 763 genes showed changes in expression. Among 59 genes with changes in the neuron category, 39 genes were upregulated and 20 were downregulated. Some genes linked to immunity, inflammation, and stress were also upregulated. In contrast, most genes showing changes in the energy and muscle categories were downregulated (Table 1) .
DISCUSSION
The total number of genes showing changes in expression (mean values for the patients) in patients with MD was 174, while that in patients with SD was 763. The total number of genes that showed changes in expression in both groups of patients was 25, while that of genes that agreed with the direction of the fluctuation included only 13 types. These findings indicated that MD differs from SD in patients with Bell's palsy.
Considering these findings, we can assume that facial nerve conduction is reduced in MD; therefore, the orbicularis oculi muscle cannot function well, and patients present with paresis. To improve this situation, muscle tissue regeneration is promoted. It has been reported that innervation is required for normal energy production in muscles [1] . Accordingly, energy production decreases in muscles with paresis due to denervation, but there was some energy production related to muscle tissue regeneration in patients with MD. Because facial nerve conduction is largely abolished in SD, there was very little energy production in or regeneration of affected muscles. Therefore, muscles innervated by the facial nerve did not show much regeneration, but the neurons showed accelerated regeneration.
On the basis of these molecular biological findings, we suggest that facial nerve neurorrhaphy and nerve grafting are suitable for patients with MD. These procedures will improve facial nerve conduction, leading to increased energy production for muscle tissue regeneration. However, there was very low energy production and little muscle regeneration in patients with SD, although they showed neuronal regeneration acceleration. These findings may explain why facial nerve neurorrhaphy and nerve grafting are unsuccessful if performed more than one year after facial paralysis onset. Authors have reported that recovery is better if the interval between facial nerve injury and nerve repair surgery is short . Because improvement in facial nerve conduction is incomplete in patients with SD, we consider that promoting muscle tissue regeneration and energy production is necessary. Regenerative medicine, such as the use of induced pluripotent stem cells, can be used to improve muscle regeneration. However, it will take time for such treatment to become available for clinical use; therefore, we propose the administration of pyruvate or mitochonic acid 5 (MA-5) as a practical means to promote muscle regeneration and energy production. Pyruvate plays a pivotal role in the metabolism of carbohydrates, amino acids, and lipids. It is the end product of glycolysis and can be utilized in any of the three pathways. (1) It is reduced to form lactate and NAD + ; (2) it is oxidized by pyruvate dehydrogenase complex (PDHC) to yield acetyl-CoA; and (3) it is carboxylated by pyruvate carboxylase to form oxaloacetate for the anaplerosis to replenish tricarboxylic acid (TCA) cycle intermediates.
Thus, pyruvate administration restores adenosine 5'-triposphate (ATP) production via the glycolytic pathway. MA-5 targets the mitochondrial protein mitofilin at the crista junction of the inner membrane and can be a novel agent for treating diseases associated with mitochondrial dysfunction [5, 6] . In patients with SD having Bell's palsy, mitochondrial cytopathy may develop with ATP synthesis impairment. As this state is similar to that seen in various mitochondrial diseases, we consider that therapy with pyruvate and MA-5 could be effective [7, 8] . We also propose neurovascular free muscle transfer as an effective surgery for patients with SD having Bell's palsy. Neurovascular free muscle transfer is one of the main reconstruction options for established or long-standing facial paralysis, but it also seems to be suitable for severe Bell's palsy based on our molecular biological findings, and we suggest that neurovascular free muscle transfer is more effective than facial nerve neurorrhaphy with nerve grafting in patients with SD [9] .
CONCLUSION
We conclude that the gene expression in Bell's palsy changes with the degree of facial nerve palsy. It is expected that this study will aid in the development of new treatments and diagnostic/prognostic markers based on the severity of facial nerve palsy.
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